CRISPR Therapeutics AG

Suisse


 
Quantité totale PI 369
Rang # Quantité totale PI 3 468
Note d'activité PI 3,3/5.0    371
Rang # Activité PI 1 913
Symbole boursier
ISIN CH0334081137
Capitalisation 4,499M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Services scientifiques, technolo...

Brevets

Marques

153 18
54 4
133 5
2
 
Dernier brevet 2025 - Modulating expression of alas1 (...
Premier brevet 2014 - Crispr-cas system materials and ...
Dernière marque 2025 - CTX213
Première marque 2018 - CRISPR COLLECTIVE

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 P/S Cells for medical or clinical use in the field of stem cell therapy for the treatment of diabetes...
2024 Invention Methods and compositions for treating lipoprotein-related diseases. The present disclosure relat...
Invention Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene. The present disclosure relat...
Invention Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene. The present disclosure rela...
Invention Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions. The pres...
P/S Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment ...
Invention Gene editing for hemophilia a with improved factor viii expression. Provided herein, in some emb...
Invention Compositions and methods for the depletion of cd117+ cells. The invention provides compositions ...
Invention Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (ptk7) and immune cel...
Invention Compositions and methods for gene editing. The present application provides materials and method...
Invention Methods and assays for off-target analysis. The present disclosure provides methods, assays, nucl...
P/S Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment ...
P/S Medical and veterinary preparations and articles; pharmaceuticals; pharmaceutical and biopharmace...
Invention Materials and methods for treatment of glycogen storage disease type 1a. The present application...
2023 Invention Materials and methods for treatment of alpha-1 antitrypsin deficiency. The present application p...
P/S Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment...
P/S Scientific research and development, namely, gene editing for researching and developing human ce...
Invention Compositions and methods for gene editing for hemophilia a. Provided include materials and metho...
Invention Compositions and methods for genomic editing by insertion of donor polynucleotides. The present ...
Invention Genetically engineered anti-cd19 car-t cells for use in treating b-cell malignancies. TRACβ2MRegn...
Invention Genetically engineered anti-cd19 car-t cells for use in treating b-cell malignancies. Methods fo...
Invention Use of anti-cd117 antibody drug conjugate (adc). The invention relates to uses of an anti-CD117 a...
Invention Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20. Genetica...
P/S Education services, namely, providing on-line non-downloadable articles and newsletters in the f...
Invention Method for detecting mycoplasma contamination. M. arginini, M. orale, M. synoviae, M. hyorhinis, ...
Invention Genetically engineered immune cells having disrupted transporter associated with antigen processi...
Invention Viral detection assays. Methods, compositions and kits for detection of one or more of Human Parv...
Invention Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses. ...
Invention Compositions and methods for treating human immunodeficiency virus. in vivoCCR5CCR5 gene to treat...
Invention Methods and compositions for in vivo editing of stem cells. in vivoin vivo editing of stem cells ...
Invention Base editing proteins and uses thereof. The present disclosure provides base editing fusion prote...
Invention Cd117-targeting nanoparticles for use in drug delivery. Single domain antibody fragments binding ...
Invention Chimeric antigen receptor specific to cd117. A chimeric antigen receptor (CAR) that binds CD117 (...
Invention Lipid nanoparticles (lnps)-based ocular delivery. Provided herein include compositions, methods ...
Invention Lipid nanoparticles (lnps)-based ocular delivery. MYOCMYOC) gene in the trabecular meshwork cells...
Invention System and method of generating test deviations. Disclosed herein include systems, devices, and m...
Invention Gene-edited natural killer cells. B2MCIITA FASCISHCD38FLI1TGFBR1TGFBR2TGFBR2 gene, an inserted po...
Invention Compositions and methods for differentiating stem cells into nk cells. The disclosure features me...
Invention Picornaviral vectors for gene editing. The present disclosure relates to picornaviral vectors, me...
Invention Cas9 antibodies and uses thereof. Provided include antibodies or fragments thereof having specifi...
Invention Guide design and off-target searches. Disclosed herein include systems, devices, and methods for ...
Invention Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption. A population of genetically engi...
Invention Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof. Genetically enginee...
Invention Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption. A population of genetically engin...
Invention Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof. TRACβ2MRegnase1TGFBR...
Invention Methods and compositions for treating lipoprotein-related diseases. The present disclosure relate...
Invention Materials and methods for engineering cells and uses thereof in immuno-oncology. Materials and m...
Invention Multiplex gene edited cells for cd70-directed cancer immunotherapy. Several embodiments of the m...
Invention Materials and methods for treatment of friedreich ataxia and other related disorders. The presen...
Invention Universal donor cells. Genetically modified cells that are compatible with multiple subjects, e....
2022 Invention Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) ...
Invention Gene editing for hemophilia a with improved factor viii expression. Provided herein, in some embo...
P/S Cells for medical or clinical use. Pharmaceutical research and development, hereunder, gene editing.
P/S Cells for medical or clinical use in the field of CAR T cell therapy for the treatment of cancer ...
P/S Cells for medical or clinical use in the field of CAR T cell therapy for the treatment of hematol...
2021 Invention Materials and methods for treatment of amyotrophic lateral sclerosis. The present application pr...
P/S Education services, namely, providing on-line non-downloadable articles and newsletters in the fi...
2020 Invention Cd70+ solid tumor therapy using genetically engineered t cells targeting cd70. Aspects of the pr...
2019 P/S Human cells for medical and clinical use, namely, for the treatment of human diseases in the natu...
2018 P/S Reagents for scientific and research use; kits composed of reagents for scientific and research ...
P/S Education services, namely, providing online non-downloadable articles and newsletters in the fie...